116 related articles for article (PubMed ID: 37166880)
1. HORMONE-RECEPTOR -POSITIVE BREAST CANCER: DIFFERENT PROGNOSIS OF BONE METASTASIS AMONG MOLECULAR SUBTYPES.
Tevzadze M; Kakhadze S; Baramia M; Rukhadze T; Khatashvili Z; Mirzaey S
Georgian Med News; 2023 Mar; (336):54-58. PubMed ID: 37166880
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
3. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
5. Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer.
Howland NK; Driver TD; Sedrak MP; Wen X; Dong W; Hatch S; Eltorky MA; Chao C
J Surg Res; 2013 Dec; 185(2):697-703. PubMed ID: 24095025
[TBL] [Abstract][Full Text] [Related]
6. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients.
Hashmi AA; Aijaz S; Khan SM; Mahboob R; Irfan M; Zafar NI; Nisar M; Siddiqui M; Edhi MM; Faridi N; Khan A
World J Surg Oncol; 2018 Jan; 16(1):1. PubMed ID: 29291744
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database.
Kim YJ; Kim JS; Kim IA
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1803-1816. PubMed ID: 29971531
[TBL] [Abstract][Full Text] [Related]
8. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial.
Falck AK; Fernö M; Bendahl PO; Rydén L
BMC Cancer; 2013 Nov; 13():558. PubMed ID: 24274821
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia.
Anwar SL; Avanti WS; Nugroho AC; Choridah L; Dwianingsih EK; Harahap WA; Aryandono T; Wulaningsih W
World J Surg Oncol; 2020 May; 18(1):117. PubMed ID: 32473643
[TBL] [Abstract][Full Text] [Related]
10. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
11. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases.
Elidrissi Errahhali M; Elidrissi Errahhali M; Ouarzane M; El Harroudi T; Afqir S; Bellaoui M
BMC Womens Health; 2017 Jan; 17(1):3. PubMed ID: 28068979
[TBL] [Abstract][Full Text] [Related]
12. Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.
Xiao Y; Zhang S; Hou G; Zhang X; Hao X; Zhang J
Tumour Biol; 2014 Mar; 35(3):2035-45. PubMed ID: 24096546
[TBL] [Abstract][Full Text] [Related]
13. Hormone receptors and HER-2 status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative Asian patients treated with breast conservation therapy.
Wong FY; Chin FK; Lee KA; Soong YL; Chua ET
Ann Acad Med Singap; 2011 Feb; 40(2):90-6. PubMed ID: 21468463
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab.
McGuire A; Kalinina O; Holian E; Curran C; Malone CA; McLaughlin R; Lowery A; Brown JAL; Kerin MJ
Breast Cancer Res Treat; 2017 Jul; 164(1):221-229. PubMed ID: 28378298
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
16. Pattern of distant metastasis in molecular subtypes of carcinoma breast: An institutional study.
Kunikullaya SU; Poddar J; Sharma AD; Patel S
Indian J Cancer; 2017; 54(1):327-332. PubMed ID: 29199716
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of breast cancer metastasis and mortality rates based on molecular subtype: A description study.
Kurniawan BN; Ferianto D; Pieter J
Breast Dis; 2022; 41(1):427-432. PubMed ID: 36591651
[TBL] [Abstract][Full Text] [Related]
19. Pathological features and prognosis of different molecular subtypes of breast cancer.
Wang GS; Zhu H; Bi SJ
Mol Med Rep; 2012 Oct; 6(4):779-82. PubMed ID: 22797840
[TBL] [Abstract][Full Text] [Related]
20. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
